RAAS | Jotup

NYSE to Suspend Trading in Cloopen Group Holding Limited (RAAS) and Commence Delisting Proceedings

Retrieved on:

Wednesday, May 17, 2023

Professional Services, Finance, Form 6-K, Exchange, Committee, RAAS, New York Stock Exchange, Security (finance), NYSE, Cryptocurrency

The New York Stock Exchange (“NYSE” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the American depositary shares (the “ADSs”) of Cloopen Group Holding Limited (the “Company”) ─ ticker symbol RAAS ─ from the NYSE.

Key Points:

The New York Stock Exchange (“NYSE” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the American depositary shares (the “ADSs”) of Cloopen Group Holding Limited (the “Company”) ─ ticker symbol RAAS ─ from the NYSE.
Trading in the Company’s ADSs will be suspended immediately.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange.
The NYSE will apply to the Securities and Exchange Commission to delist the ADSs upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

Ibotta Performance Network Solves Loyalty Problem Challenges; Debuts 3x ROAS Guarantee

Retrieved on:

Monday, May 15, 2023

IPN, Advertising, Sale, Acquisition, Walmart, Mass, Risk, RAAS, Coffee, Online shopping, Sales, Ibotta

DENVER, May 15, 2023 (GLOBE NEWSWIRE) -- As the Ibotta Performance Network (IPN) celebrates its first anniversary, Ibotta, the leading performance marketing platform, debuts a new program that guarantees 3x return on advertising spend (ROAS) for brands and manufacturers who choose to participate.

Key Points:

DENVER, May 15, 2023 (GLOBE NEWSWIRE) -- As the Ibotta Performance Network (IPN) celebrates its first anniversary, Ibotta, the leading performance marketing platform, debuts a new program that guarantees 3x return on advertising spend (ROAS) for brands and manufacturers who choose to participate.
“Our vision for the Ibotta Performance Network is to deliver performance marketing at unprecedented scale, and we have done just that, thanks in large part to our network partners like Walmart and Dollar General," said Bryan Leach, founder and Chief Executive Officer at Ibotta.
Advertisers on the Ibotta Performance Network average nearly a 50% lift in incremental units sold, with 42% of conversions being new-to-brand.
To learn more about the Ibotta Performance Network, visit ipn.ibotta.com .

EQS-News: APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary prophylaxis of cardiovascular events - market launch already planned for early 2024

Retrieved on:

Friday, April 28, 2023

Hypertension, Hyperlipidemia, EUR, Ticker, Patient, Physician, RAAS, Mortality, Pharmaceutical industry

APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pills in the German market, with an additional short-term in-licensing is offering for the first time a Single Pill with two active ingredients for primary prophylaxis.

Key Points:

APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ), a leading pharmaceutical company specializing in Single Pills in the German market, with an additional short-term in-licensing is offering for the first time a Single Pill with two active ingredients for primary prophylaxis.
Two Single Pills from APONTIS PHARMA are already available on the market for the secondary prophylaxis of cardiovascular events.
At present, ten Single Pills from APONTIS PHARMA are on the market in Germany for the treatment of cardiovascular diseases.
The new Single Pill is the 14th announced launch in APONTIS PHARMA's Single Pill pipeline.

Pan Am Flight Academy Acquires State-of-the-Art B737 MAX-8 Simulator

Retrieved on:

Tuesday, April 11, 2023

Runway Awareness and Advisory System, Aviation, CTP, Multimedia, B737, Aircraft, Pan Am, Organization, Student, Pan Am Flight 812, RAAS, TCAS, Airline

MIAMI, April 11, 2023 /PRNewswire/ -- Pan Am Flight Academy, a leading aviation training provider, has acquired a new Level D B737 MAX-8 simulator to enhance its commercial pilot training programs.

Key Points:

MIAMI, April 11, 2023 /PRNewswire/ -- Pan Am Flight Academy, a leading aviation training provider, has acquired a new Level D B737 MAX-8 simulator to enhance its commercial pilot training programs.
The state-of-the-art simulator is expected to be ready for training by July 2023 enabling Pan Am to incorporate a new aircraft sim to its extended offering.
"We are excited to add the B737 MAX-8 simulator to our fleet of training devices," said Jeff Portanova, President of Pan Am Flight Academy.
The B737 MAX-8 is one of the most popular commercial aircraft in the world, and with the new simulator, Pan Am Flight Academy will be able to offer further training options to pilots from airlines and other aviation organizations worldwide.

Cloopen Regains Compliance with NYSE Minimum Price Requirement

Retrieved on:

Tuesday, April 4, 2023

RAAS, NYSE, ADS, Cryptocurrency

BEIJING, April 4, 2023 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced that, based on a notification letter the Company received from the New York Stock Exchange (the "NYSE") on April 3, 2023, the Company has regained compliance with the NYSE's continued listing standard for minimum share price.

Key Points:

BEIJING, April 4, 2023 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced that, based on a notification letter the Company received from the New York Stock Exchange (the "NYSE") on April 3, 2023, the Company has regained compliance with the NYSE's continued listing standard for minimum share price.
On October 5, 2022, the NYSE notified the Company that it was not in compliance with the NYSE's continued listing standards because, as of October 4, 2022, the average closing price of the Company's American depositary shares (the "ADSs") was less than US$1.00 per ADS over a consecutive 30 trading-day period.
On April 3, 2023, the Company received a confirmation from the NYSE that a calculation of the Company's average ADS price for the 30-trading days ended March 31, 2023 indicated that the Company's ADS price was above the NYSE's minimum requirement of US$1.00 based on a 30-trading day average.
As a result, the Company has regained compliance within the prescribed time, and the ADSs will continue to be traded on the NYSE, subject to the Company's continued compliance with all applicable continued listing standards.

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Retrieved on:

Saturday, March 4, 2023

RADNOR, Pa., March 04, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced positive data from the Target-HTN Phase 2 study that demonstrated clinically meaningful blood pressure reduction with once-daily dosing of lorundrostat at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC) going on now in New Orleans, LA. In a pre-specified analysis, hypertensive subjects with a BMI ≥30 kg/m2, demonstrated a statistically significant reduction of placebo-adjusted change in systolic blood pressure (BP) of 16.7 mmHg (p=0.002) with 50mg QD and a reduction of 12.3 mmHg (p=0.030) with 100 mg QD in Part 1 of the study.

Key Points:

“We continue to be excited by the compelling data from our Target-HTN trial.
As rates of hypertension and obesity continue to evolve, so must our approach to treatment,” said David Rodman, M.D., Chief Medical Officer of Mineralys.
During ACC.23/WCC, the Company will also present Phase 1 data for lorundrostat that is included in a poster titled, “First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor”.
The poster will be made available on the Company’s website here on March 5, 2023.

Cloopen Announces ADS Ratio Change

Retrieved on:

Friday, March 3, 2023

RAAS, ADS, Sale, NYSE, Book, Security (finance)

BEIJING, March 3, 2023 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced that it will change the ratio of its American depositary shares ("ADSs") to Class A ordinary shares from one (1) ADS representing two (2) Class A ordinary shares to one (1) ADS representing six (6) Class A ordinary shares.

Key Points:

BEIJING, March 3, 2023 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced that it will change the ratio of its American depositary shares ("ADSs") to Class A ordinary shares from one (1) ADS representing two (2) Class A ordinary shares to one (1) ADS representing six (6) Class A ordinary shares.
For Cloopen's ADS holders, this ratio change will have the same effect as a 1-for-3 reverse ADS split.
Furthermore, no physical action by ADS holders will be required to effect the ratio change, as the change will be effected on the books of the depositary.
As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although Cloopen can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than three times the ADS price before the change.

National Kidney Foundation Launches New Public Education Series on Hyperkalemia

Retrieved on:

Thursday, March 2, 2023

NEW YORK, March 2, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF) has launched a new animated video series to educate people with Advanced Chronic Kidney Disease (CKD), on the heightened risk for complications with hyperkalemia (high potassium). Two patient-friendly videos were developed, each ranging from about one and a half to two and a half minutes, and are available in both English and Spanish to help people of varying levels of health literacy and diverse backgrounds better understand this condition. To understand the lived experiences of those who have this disease, NKF also developed patient videos in English and Spanish. This two-part educational animated video series is supported by AstraZeneca.

Key Points:

NEW YORK, March 2, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF) has launched a new animated video series to educate people with Advanced Chronic Kidney Disease (CKD) , on the heightened risk for complications with hyperkalemia (high potassium) .
To understand the lived experiences of those who have this disease, NKF also developed patient videos in English and Spanish .
Managing high potassium in the blood is possible once you understand the link between the condition & other conditions!
"
If hyperkalemia is severe, it can sometimes cause heart rhythm irregularities and even sudden death," said Dr. Joseph Vassalotti, Chief Medical Officer for the National Kidney Foundation.

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

Retrieved on:

Monday, February 20, 2023

Obesity, American College, RAAS, Therapy, Congress, Abstract, Pharmaceutical industry

RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, announced today that abstracts featuring lorundrostat clinical data from both Phase 2 and Phase 1 studies have been selected for a moderated poster presentation and poster presentation at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC), which is scheduled to take place in New Orleans, LA, on March 4-6, 2023.

Key Points:

RADNOR, Pa., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, announced today that abstracts featuring lorundrostat clinical data from both Phase 2 and Phase 1 studies have been selected for a moderated poster presentation and poster presentation at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC), which is scheduled to take place in New Orleans, LA, on March 4-6, 2023.
Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation

Cloopen Announces the Appointment of HKCM as Independent Auditor

Retrieved on:

Friday, February 3, 2023

Florida Board of Accountancy, NYSE, P.C, Form, RAAS, Disagreement, Tax advisor

BEIJING, Feb. 3, 2023 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced the appointment of HKCM CPA & Co ("HKCM") as the Company's independent registered public accounting firm to replace Yu Certified Public Accountant, P.C.

Key Points:

BEIJING, Feb. 3, 2023 /PRNewswire/ -- Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced the appointment of HKCM CPA & Co ("HKCM") as the Company's independent registered public accounting firm to replace Yu Certified Public Accountant, P.C.
The change of the Company's independent auditor was made after careful consideration and evaluation process and was approved by the board of directors of the Company (the "Board") and the audit committee of the Board.
Prior to the engagement of HKCM, neither the Company nor anyone acting on its behalf consulted HKCM regarding any of the matters or events set forth in Item 16F(a)(2)(i) and (ii) of Form 20-F.
The Company is working closely with Yu CPA and HKCM to ensure a seamless transition.